Mydecine Innovations Group Receives Shareholder and Court Approval for Spin-Out of Cannabis Subsidiaries
Completion of the Arrangement and the spin-out transaction remains subject to certain conditions, including final acceptance by the Aequitas Neo Exchange. If the approval of the Aequitas Neo Exchange is received and all other conditions precedent to the Arrangement are satisfied or waived, Mydecine expects to complete the Arrangement on or about
At the Meeting, six of the seven director nominees listed in Mydecine's management information circular dated
Nominee: |
Votes For: |
% Votes For |
Votes Withheld |
%Votes Withheld |
|
42,323,083 |
|
4,575,099 |
|
|
44,569,486 |
|
2,328,696 |
|
|
45,442,567 |
|
1,455,615 |
|
|
45,432,115 |
|
1,466,067 |
|
|
45,435,948 |
|
1,462,234 |
|
Dr. |
42,875,838 |
|
4,022,344 |
|
In addition, at the Meeting, Mydecine shareholders approved the appointment of
On behalf of the Board of Directors:
“
About
Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.
Forward-Looking Statements
This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management’s current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Forward looking-information in this news release includes, but is not limited to: statements with respect to completion of the Arrangement; benefits of the Arrangement; and timing of closing of the Arrangement. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210924005545/en/
Media
LS2group
cryan@ls2group.com
515-770-4823
Investors
corp@mydecineinc.com
1-720-277-9879
myco@kcsa.com
1-212-896-1267
Source: